You are here:
NICE
NICE Guidance
Conditions and diseases
Blood and immune system conditions
Blood and bone marrow cancers
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
Technology appraisal guidance
Reference number:
TA218
Published:
23 March 2011
Guidance
Tools and resources
Information for the public
History
Download guidance (PDF)
Overview
1 Guidance
2 The technology
3 The manufacturer's submission
4 Consideration of the evidence
5 Implementation
6 Recommendations for further research
7 Related NICE guidance
8 Review of guidance
Appendix A: Appraisal Committee members and NICE project team
Appendix B: Sources of evidence considered by the Committee
Changes after publication
7 Related NICE guidance
Improving outcomes in haematological cancers.
NICE cancer service guidance (2003).
Next page
8 Review of guidance
Previous page
6 Recommendations for further research